A Cell Type Selective YM155 Prodrug Targets Receptor-Interacting Protein Kinase 2 to Induce Brain Cancer Cell Death

Area of Science:

• Oncology
• Pharmacology
• Neuroscience

Background:

• Glioblastoma (GBM) is an aggressive brain cancer with limited treatment options.
• YM155, a potent anti-cancer drug, inhibits survivin but lacks cell-type selectivity, causing tolerability issues.
• Developing targeted therapies for GBM remains a critical unmet need.

Purpose of the Study:

• To design and synthesize a prodrug of YM155 (aYM155) for improved glioblastoma treatment.
• To evaluate the cell-killing activity, selectivity, and brain penetration of aYM155.
• To elucidate the mechanism of action of YM155 and its prodrug.

Main Methods:

• Synthesis and characterization of the YM155 prodrug, aYM155.
• In vitro evaluation of cell-killing activity against patient-derived GBM cells and EGFR-amplified cell lines.
• Mass spectrometry to analyze prodrug activation rates and brain penetration (brain-to-plasma ratio).
• In vivo assessment of aYM155 efficacy in an orthotopic intracranial GBM xenograft model.

Main Results:

• aYM155 demonstrated potent cell killing activity against GBM cancer stem-like cells and EGFR-amplified cell lines.
• Prodrug activation was cell-type dependent, enhancing selectivity for transformed cells.
• aYM155 exhibited improved brain transport compared to the parent drug YM155.
• YM155's anti-cancer effects were linked to survivin suppression and apoptosis induction via RIPK2 interaction.
• aYM155 significantly inhibited GBM tumor growth in vivo with selective pharmacodynamic effects.

Conclusions:

• aYM155 represents a promising prodrug strategy for glioblastoma, offering enhanced selectivity and brain penetration.
• The prodrug's efficacy is mediated by cell-type selective activation and targeting of the survivin/RIPK2 pathway.
• Further investigation of aYM155 is warranted for its potential clinical application in treating GBM.